LUHUA WANG to Remission Induction
This is a "connection" page, showing publications LUHUA WANG has written about Remission Induction.
Connection Strength
0.379
-
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31; 122(18):3122-8.
Score: 0.072
-
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol. 2012 Dec; 35(6):562-5.
Score: 0.068
-
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology. 2010 Apr; 15(2):70-3.
Score: 0.057
-
CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant. 2010 Mar; 45(3):498-504.
Score: 0.054
-
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007 Jun; 12(3):235-9.
Score: 0.046
-
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005 Jul; 79(3):194-7.
Score: 0.041
-
Value of novel agents and intensive therapy for patients with multiple myeloma. Bone Marrow Transplant. 2014 Mar; 49(3):422-5.
Score: 0.018
-
Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011 Apr; 46(4):510-5.
Score: 0.014
-
Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol. 2003 Oct; 40(4 Suppl 4):3-7.
Score: 0.009